Skip to content

G&A at other companies

iRadimed logo
iRadimedIRMD
$4.57M-0.9%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$4.84M+19.7%
Neuronetics logo
NeuroneticsSTIM
$13.05M-0.7%
AngioDynamics logo
AngioDynamicsANGO
$10.72M+2.2%

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's G&A?
Stereotaxis (STXS) reported G&A of $4.76M in Q1 2026.
How has Stereotaxis's G&A changed year-over-year?
Stereotaxis's G&A increased by 5.9% year-over-year, from $4.5M to $4.76M.
What is the long-term trend for Stereotaxis's G&A?
Over 4 years (2021 to 2025), Stereotaxis's G&A has grown at a 6.3% compound annual growth rate (CAGR), from $13.97M to $17.85M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.